COVID-19 Impact on Non-Small Cell Lung Cancer Treatment (NSCLC) Industry:
Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic. Even for patients who were non-COVID-19, the disturbance of regular hospital services, such as imaging and treatment appointments, had a significant impact on the physical and mental well-being of these patients. The stress placed on the availability of medical resources and hospitals has reduced the clinical admissions to most other departments, including oncology departments. Consequently, the benefits some cancer patients could have received have been compromised due to treatment delay declining the market in 2020.
Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size has reached US$ 17.75 Billion in 2021
The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries. Other reasons contributing to the expansion of the non-small cell lung cancer treatments market include an increase in the proportion of smokers and exposure to toxins such as asbestos. According to our estimates, the Non-Small Cell Lung Cancer (NSCLC) Market will grow at a 6.4% CAGR from 2021 to 2027.
Adenocarcinoma Is the Most Prevalent Segment Histologically:
Our report classified the histological segment into three categories: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared to the other two forms, adenocarcinoma is the most common and is found in the cells responsible for mucous secretion in the outer lung sections. Furthermore, Squamous Cell Carcinoma, located in the squamous cells near the bronchus in the middle of the lungs, is one of the fastest expanding segments in the market. Large cell carcinoma, also known as undifferentiated carcinoma, can develop in any section of the lungs, is the fastest-growing, and is the most difficult to cure.
Immunotherapy Market Share is Estimated to Be the Largest:
By treatment, immunotherapy is expected to have the most significant market share. According to our estimates, the targeted therapy category will grow during the projection period. The increasing number of product launches, particularly in the immunotherapy area, is credited with the market domination. Immunotherapy is currently being used more widely in emerging countries, owing to improved patient outcomes resulting from effective treatment.
Regional Analysis:
In our report, we have examined the regions like North America, Europe, Asia-Pacific, Rest of The World. Lung cancer is becoming more common, and innovative therapies and are becoming more widely used, making the North America, Europe & Asia Pacific the most powerful region worldwide. Due to a rise in lung cancer diagnoses, India and China in the Asia Pacific region are seeing growth in NSCLC therapies. Chemotherapy is the most common kind of treatment in these underdeveloped countries. However, advanced immunotherapies and targeted medicines are seeing rising adoption and investment in nations like United States, Germany, United Kingdom, and Japan.
Key Market Players:
Our report examines AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & Co Inc., Novartis, and Pfizer Inc. as leading players in the Non-Small Cell Lung Cancer Treatment (NSCLC) Market. The majority of significant market players are also concentrating on continuous advancements in advanced therapies and improving the efficacy of existing medicines. These businesses are receiving product approvals as well.
The publisher's latest report Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Histology Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), End User (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics, Others), Region (North America, Europe, Asia-Pacific, Rest of The World), Companies (AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & co Inc., Novartis, Pfizer Inc.) provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.
Histology Type - Market has been covered from 3 viewpoints:
1. Adenocarcinoma
2. Squamous Cell Carcinoma
3. Large Cell Carcinoma
Treatment Type - Market has been covered from 5 viewpoints:
1. Chemotherapy
2. Immunotherapy
3. Radiation Therapy
4. Surgery
5. Targeted Therapy Drugs
Drug Class - Market has been covered from 6 viewpoints:
1. Angiogenesis Inhibitor
2. Epidermal Growth Factor Receptor Blocker
3. Kinase Inhibitor
4. Microtubule Stabilizer
5. Folate Antimetabolites
6. PD-1/ PD-L1 Inhibitor
End User - Market has been covered from 4 viewpoints:
1. General Medical & Surgical Hospitals
2. Specialty Hospitals
3. Clinics
4. Others
Region - Market has been covered from 4 viewpoints:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of The World
Company Insights:
- Overview
- Recent Development
- Revenue
Key Players:
1. AbbVie Inc.
2. Astellas Pharma
3. AstraZeneca
4. Avid Bioservices Inc.
5. Bayer Healthcare
6. Biogen Inc.
7. Blueprint Medicines Corp
8. Eli Lilly and Company
9. Merck & co Inc.
10. Novartis
11. Pfizer Inc.
Table of Contents
Companies Mentioned
- AbbVie Inc.
- Astellas Pharma
- AstraZeneca
- Avid Bioservices Inc.
- Bayer Healthcare
- Biogen Inc.
- Blueprint Medicines Corp
- Eli Lilly and Company
- Merck & co Inc.
- Novartis
- Pfizer Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2022 |
| Forecast Period | 2021 - 2027 |
| Estimated Market Value ( USD | $ 17.75 Billion |
| Forecasted Market Value ( USD | $ 25.71 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
